SRGA - Aziyo Biologics to price IPO on Oct. 7th; competitors include ABBV MDT SRGA and SYK

Aziyo Biologics, Inc. is slated to price its IPO on Wednesday, October 7th.From the prospectus:"We are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material. Our proprietary products, which we refer to as our Core Products, are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets, which represented a combined $3 billion market opportunity in the United States in 2019. To expand our commercial reach, we have commercial relationships with major medical device companies, such as Boston Scientific and Medtronic, to promote and sell some of our Core Products. We believe our focus on our unique regenerative medicine platforms

For further details see:

Aziyo Biologics to price IPO on Oct. 7th; competitors include ABBV, MDT, SRGA and SYK